



The current state of AMR research activities including Alternative to antimicrobials (ATA) and collaboration opportunities in VIETNAM

Thu Thuy Nguyen, Deputy Director General, Department of Animal Health, Viet Nam

Background on AMR research in the Vietnam

- What is the current status of AMR research in Vietnam?
- -National Action Plan on Antimicrobial Resistance Prevention and Control in the Agricultural Sector for the 2021-2025 Period (Decision No. 3609/QD-BNN-TY dated August 23, 2021, of the Ministry of Agriculture and Rural Development)
- -Framework for scientific research tasks on the use of antibiotics, antibiotic resistance, and alternatives to antibiotics in livestock and aquaculture in the period 2024-2030 (Decision No. 3492/QD-BNN-TY dated August 17, 2023)
- Various studies on the molecular epidemiology, pathogenicity, and transmission of antibiotic-resistant bacteria isolated from animals, foods of animal origin, and farm environments.
- Who are the key stakeholders on the AMR research? (e.g. Government, Academic, Private sector):
- Academic sector: Vietnam National University of Agriculture (VNUA), National Institute of Veterinary Research

ATA Research Focus

- What is the state of research on ATA in your country? e.g., vaccines, phage therapy, antimicrobial peptides
- - In the framework for scientific research tasks, phage therapy was selected as a priority for researching an alternative to antibiotics in livestock in the period 2024-2030
- - Current researches focus on evaluating the efficacy of bacteriophages, engineered phages, phage enzymes (endolysin), and phages combined with antibiotics/bacteriocins/herbals in the prevention and treatment of animal diseases
- What are the regulatory or practical barriers to developing ATA-based treatments in Vietnam?
- Lack of established regulatory pathways for phage therapy in Vietnam
- High research and development costs for phage therapy

Challenges related to AMR/ATA research

- **Challenge 1:** The isolation, characterization, and production of phages at a large scale can be time-consuming and expensive
- **Challenge 2:** It requires collaboration across disciplines (microbiology, biotechnology) to produce effective phage therapy to control animal diseases
- **Challenge 3:** Determine the effective delivery methods of phage preparations
- **Challenge 4:** Lack of data to prove the efficacy and safety of phage therapy in vivo

Solutions

- **Solution 1:** Continue optimizing the procedures for the development of bacteriophage preparations (phages, engineered phages, phage enzymes, combinations of phage with other antibacterial agents)
- **Solution 2:** Promoting multi-sectoral collaboration to develop effective phage therapy against animal diseases
- **Solution 3:** Continue studying the delivery methods of phage preparations
- **Solution 4:** Conduct clinical trials at a large scale to demonstrate the efficacy and safety of phage therapy

Collaboration opportunities

Do you have any requests for collaboration with or support from other countries on specific topics?: Request for collaboration with or support (technologies, financial support) from other countries (Japan, US, EU...) on research and development of phage therapy in the prevention and treatment of animal disease